Tumor imaging

Assoc. prof. V. Marković, MD, PhD
Assoc. prof. A. Punda, MD, PhD
A. Barić, MD, nucl. med. spec.
Radiotracers

1. Ga-67
2. Tc-99m-diphosphonate
3. J-131
4. J-131-MIBG
5. In-111-pentetreotide (Octreotide, Octreoscan)-somatostatin receptor imaging
6. F-18-FDG
7. Labeled monoclonal antibodies imunoscinography
GALLIUM -67 CITRATE SCINTIGRAPHY

Tumor diagnostic
Radiotracer and its biodistribution mechanism

- Gallium is rare metal, chemical element in group 13 (III a) of the periodic table (In, Al), cyclotron-produced (from Zn-68)
- Y rays: 93 (38%), 184 (24%), 296 (16%) i 388 (4%) keV; $T_{1/2} = 78$ hours
- It is used in form of citrate, intravenous
- Adults: 3-5 mCi
- Children: 0.04- 0.07 mCi/kg, minimum 0.25 mCi
- Time of the scan- tumors: 48-72 h post injection
- Time of the scan- infections: 6-24 h post injection
TUMOR CELLS BIND GALLIUM-TRANSFERRIN COMPLEX IN DEPENDANCE ON TRANSFERRIN RECEPTOR EXPRESSION

- Ga-67 binds on plasma proteins in blood: transferrin and haptoglobin
- In tumor cells Ga-67 binds on ferritin (it has high concentration in lymphoma cells and other tumors)
- Ga-67 binds on lactoferrin- lactoferrin secretion is presented in lacrimal and salivary glands, nasopharinx, spleen, bone marrow, bowel- thesee organs will have Ga-67 accumulation
- Neutrophils also have lactoferrin so Ga-67 is also used in inflammatory imaging
- Transferrin and lactoferin are metabolized in the liver so the liver acitivity is normally presented on Ga-67 scintigrams
Ga-67

- 65% Ga-67 is distributed in the body, 10 do 25% is excreted by the kidneys, 10% intestinal and 10% remains in the plasma

**Ga-67 PHYSIOLOGICAL UPTAKE**

- bones: 25% (mostly in the epiphysis of the long bones)
- liver 5%
- kidneys 2%
- spleen 1%
- nasopharinx, lacrimal and salivary glands
Ga-67

Tumors

Hodgkin and non- Hodgkin lymphoma
Hepatoma
Melanoma
Lung carcinoma
Testicular and renal carcinoma
Rhabdomyosarcoma
• Medium energy parallel collimator, large field of view gama camera

• Patient preparation with laxatives (night before scan)

• Photopeak on 93, 184, 296 i 388 keV

• Patient is in supine position
Physiological distribution of Ga-67

29-yr old female

58-yr old male
Physiological distribution of Ga-67

11-yr old girl: growth zones

73-yr old female: normal bowel uptake
Abnormal gallium activity is equal to or greater than activity in the liver
False positive findings

Postoperative location
Fracture healing
haematoma, wound healing

Pregnancy, hormonal th, menarche

Elderly, smokers

Iron supplement, hemodyalisis, chemotherapy

• Ga-67 citrate accumulation
• Ga-67 accumulation
• Accumulation in breasts
• Symetrically accumulation in the lungs
• Bone accumulation
False positive findings

• Phenobarbital, iron supplements- liver accumulation
• Chemotherapy, furosemide, fenitoin, allopurinol, ampicillin, erythromycin, cephalosporin, ibuprofen, sulfonamides, rifampin, pentamidine, phenylbutazone, phenobarbital- renal accumulation
• Phenytoin- accumulation in mediastinal and hilar lymph nodes
Indications

- Lymphoma, NHL an HL (nowedays it is widely replaced by F-18-FDG PET), usually in follow-up after therapy (decreased or disappearance of Ga-67 pathological uptake)
- Ga-67 scan must not be performed earlier then 4-6 weeks after chemotherapy
- HEPATOMA- increased focal uptake of Ca-67 on the place of scintigraphic cold areas on Tc-99m liver coloid scan
Hodgkin lymphoma

Ga-67 accumulation in lymph nodes of the neck, mediastinum, right axilla, epigastric area, paraaortal and iliac
DISSEMINATED MELANOMA IN 46-YR OLD FEMALE

INTENSIVE MULTIFOCAL UPTAKE OF Ga-67 IN THE MEDIASTINAL, BILLATERAL HILAR, PARAORTAL AND INGUINAL LYMPH NODES

LOWER ACCUMULATION (THAN PREVIOUSLY DESCRIBED) IN FRONTAL REGION OF THE BRAIN AND IN THE RIGHT AXILLARY REGION
75-yr old male with melanoma on the left shoulder, postoperative: dissemination in bilateral hilar and left infraclavicular lymph nodes

Disseminated melanoma: increased uptake in lymph nodes, lungs and bones
Melanoma

62-yr old female, 1 year after excision of the melanoma located on the right side of the face. Relapse in the scar, metastases in the right shoulder and spine
Bronchogenic lung carcinoma

Primary carcinoma in the right lung, dorsal

Multiple metastases in mediastinum, neck lymph nodes and lower parts of the left lung
Adenocarcinoma of the left kidney

68-yr old female: tumor in the left kidney with central necrosis
Tc-99m-diphosphonates

Bone tumors and bone metastasis

Primary bone cancer (osteosarcoma)
Tc99m MDP
Tc 99m MDP: Primary bone tumor (osteoblastoma)
Tc99m MDP-prostate cancer multiple metastases
I-131- diagnostic and therapy

- $\gamma$ and $\beta$ emitter
- Well differentiated thyroid cancer
- Scintigraphy:
  a) 48 hours after peroral aplication 3-5 mCi, whole body scan (head, neck, thorax, abdomen, pelvis)
  b) 5-7 days after radiiodine ablation/therapy
I-131

Papillary thyroid cancer: diffuse lung metastases
I-131-MIBG

• Metaiodobenzylguanidine (MIBG): norepinephrine analog

• Selective accumulation in tumors of neuroectodermal origin:
  - Neuroblastoma
  - Malignant pheochromocitoma
  - Medullary thyroid cancer
  - Carcinoid metastases
I-131-MIBG

Right adrenal gland pheochromocytoma
I-131-MIBG SPECT/CT

Right adrenal gland pheochromocytoma
Right adrenal gland pheochromocytoma

I-131-MIBG SPECT/CT
I-131-MIBG SPECT/CT

Right adrenal gland pheochromocytoma
NEUROBLASTOMA-EPIDEMIOLOGY

• The most common extracranial solid tumor in children (8-10% of malignant tumors)

• Half of neuroblastoma cases occur in children younger than two years, but 90% cases affects children by the age of 5 yr

• Clinical presentation is in accordance with the age of the child
PATHOLOGY

• Neuroblastoma derives from the primitive sympathetic nervous system cells

• The most common localisation:
  – adrenal glands 35%
  – retroperitoneal parasympathetic ganglia 35%
  – Mediastinal parasympathetic ganglia 20%
  – Pelvic parasympathetic ganglia <5%
  – Neck parasympathetic ganglia <5%
CLINICAL PRESENTATION

• Depends on localisation and disease stage
• Clinical symptoms:
  – Palpable tumor mass
  – Abdominal distension
  – Bulging eyes
  – Dark circles around the eyes
  – Leukemia-like symptoms (paleness, anemia, high temperature, bone pain)
  – Arthritis
DIAGNOSTIC

• Anamnesis, clinical examination

• Laboratory parameters (↑ LDH, NSE (neuron specific enolase), ferritin → bad prognostic sign)

• Genetic testing (partial deletion of chromosome 1. i 11., amplification of the MYCN oncogene)
DIAGNOSTIC

Diagnostic imaging

- CT (initial staging, localised or disseminated disease)
- MRI (better estimation of soft tissue, especially in evaluation of expansion into spinal cord and epidural space)
- US
Nuclear medicine imaging: Tc-99m-diphosphonate bone scintigraphy

- initial staging, NOT in follow-up!
- predilective location: orbits, skull bones, multiple „hot” and „cold” spots along the spine
- often symetric metastases in metaphysis of long bones, also MIBG positive
- in 60% cases accumulation is present in primary tumor
Neuroblastoma- bone metastases (Tc-99m-diphosphonate and I-123-MIBG)

A: Tc-99m-diphosphonate: normal growth zones are plane, well limited, do not involve metaphysis
B: Tc-99m-diphosphonate, blood pool phase: meta. of neuroblastoma- symmetrically increased uptake in growth zones that spreads into metaphyseal part of the bones
C: delayed scintigram: rugged, bolded growth zones spreading into tibial and femoral metaphyses
D: I-123-MIBG metastases in the growth zone areas (epiphysis)
DIAGNOSTIC

Nuclear medicine imaging:

- Somatostatin receptor scintigraphy (octreotide)
  - positive octreotide indicates a better prognosis
- Labeled antibodies scintigraphy
  - relapse, bone metastases
- PET-FDG
  - Accumulation in dependence on tumor proliferation and differentiation
  - Initially
  - I-131 MIBG scintigraphy is more specific
I-131- MIBG

Paravertebral neuroblastoma
Neuroblastoma: paravertebral location
I-131- MIBG

Preoperative

Postoperative
Bilateral pheochromocytoma

I-131- MIBG; SPECT/CT
TI-201

• Mostly used as a myocardial perfusion imaging agent

• i.v. application: early scan 20 min p.i.
  delayed scan 180 min p.i.

• In diagnostic (benign/malignant disease) and disease evaluation (after chemotherapy/ radiotherapy): brain tumors, soft tissue and bone sarcomas, Kaposi sarcoma, thyroid cancer (medullary, non I-131 avid)…
Receptor scintigraphy

- Receptor imaging using specific agonists or radiolabeled agonists

- Oncology related receptors:
  - transferrin: malignant tumors, sarcoidosis, tbc, inflammatory changes
  - somatostatine: neuroendocrine and neuroendocrine related tumors
SOMATOSTATIN RECEPTOR
SINTIGRAPHY
Neuroendocrine tumors - NET tumors

- Neuroendocrine cells arise from neural crest
- They have ability to synthesize amines, peptide hormones and neurotransmitters, and they express somatostatin receptors

Classification:
1. Carcinoids (lung, thymus, gastric, small intestine and colon)
2. Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET tm):
   a) functional: gastrinoma (most commonly), inzulinoma (benign, VIPoma, glukagonoma, somatostatinoma
   b) non-functional (15-30%)

- Tumor marker Chromogranin A is the most important for NETs, it has greatest sensitivity, irrespective of location or tumor functionality
Neuroendocrine tumors-NET tumors

- OTHER TUMORS

- Pituitary adenoma

- Tumors arising from sympathetic nervous system: pheochromocytoma, paraganglioma, neuroblastoma, ganglioneurinoma

- Medullary thyroid cancer

- Potentially may be useful in many other tumors that have somatostatin receptor expression: breast, kidney, ovarian cancer, melanoma, lymphoma, prostate cancer, glioblastoma multiforme, meningeoma
Somatostatin

- hormone, 14 amino acids, $T_{1/2} = 1-3$ min
- normally expressed in hypothalamus, cerebral cortex, brainstem, GI system, pancreas
- function: neurotransmitter or growth hormone-inhibiting hormone (GHIH) but it also inhibits insulin, glucagon and other neuropeptide secretion
- somatostatin receptors (SSR) are expressed on many cells and tumors of neuroendocrine origin
- 5 SSR subtypes
Octreotide

- a synthetic analog of somatostatin, 8 amino acids

- $T_{1/2} = 2-3$ h
In-111 pentetrotide (OctreoScan)

- In-111 (67 h, y-173, 247 keV; Auger and conversion electron, range <1um)
- Excreted mainly by the kidneys (50% of the dose during 6h, and 85% during 24h), 2% by hepatobiliary excretion
- 4h post injection 10% of the dose remains in the blood, after 24h-1%
- High affinity for SSR subtype 2 and 5, lower for SSR 3, no affinity for 1 and 4
- Well hydration must be provided- before and after injection, laxative application on the day before and during imaging time

In-111-pentetrotide= In-111-DTPA-octreotide
Patient preparation

- it is preferable to discontinue Sandostatin therapy the day before injection, and in case of an depo preparation OctreoScan may be provided just before the next treatment

- well hydration must be provided, laxative preparation before injection and during imaging (caution in patients with diarrheal syndroma)
Scintigraphy

- 3-6 mCi i.v.
- Aq. (1), 4 i 24 h p.i. (p.p. 48h), empty the bladder
- medium energy parallel collimator, 20% of energy window on both photopeaks (173 and 247 keV)
- WB; statics, SPECT (CT) of abdomen, thorax and pelvis
- spleen receives the largest radiation dose, followed by the kidneys (effective dose 12 mSv/6mCi)
Image interpretation

Physiological uptake: thyroid, spleen, liver, kidneys, hypophysis, gallbladder, urine bladder, intestine

Pathology: equal as or more intensively than in liver, present on 4h and 24 h (48h) post injection
Indications

- localisation of primary tumor
- evaluation of disease stage
- post therapy follow up
- evaluation of relapse
- assessment of radionuclide therapy
In-111-Octreotide: pancreatic tumor
Pancreatic NET, palliative surgical treatment was provided. Liver metastases.

In-111-Octreotide- SPECT
Pancreatic neuroendocrine cancer, while SPECT revealed liver metastasis.
In-111-Octreotide

Increased uptake in pancreatic NET

Carcinoid metastases in liver
Bilaterally neck paraganglioma

Pituitary adenoma

Lateral view of the head in a patient with a pituitary adenoma, which accumulates the radiotracer. The uptake in pituitary adenomas is variable, just as the uptake in the normal pituitary may vary.
Octreotide sensitivity in NETs

- carcinoid: 80%
- insulinoma: 31%
- gastrinoma: 95%
- SCLC: 100%
- PHEO: 100%
- MTC: 54%
- pituitary adenoma: 80%

The Requisites, 2006.
Tc -99m Tektrotyde

- Tc-99m labeled somatostatin receptor analogue subtypes 2,3, and 5
- i.v. 15-20 mCi, empty bladder previously
- Acquisition 2 i 4 h p.i.: WB, SPECT of abdomen, thorax and pelvis, patient may eat and drink after first scan
- Whole diagnostic procedure is done in one day, equivalent dose is lower (4, 2 mSv/20 mCi), as well as price
F-18-FDG

Left hemiabdomen neuroblastoma, metastases in left femoral bone and right fibula
Immunoscintigraphy - labeled antibodies

• Technetium labeled monoclonal antibodies
• Binding on tumor specific antigens (colon, ovary)

• Despite very well constructed theory, there are many problems according to antibody-antigen reaction (allergic reaction, production of blocking antibodies, foreign protein sensibilisation), not so huge clinical application

• Mostly in smaller tumors
Immunoscintigraphy

- Clinical application only in colon cancer and serous ovarian cancer
- Tc-99m, In-111, I-131, I-123 labeled
- Accumulation is based on antigen-antibody reaction
- Monoclonal antibodies or their fragments
Tumor markers

- Tumor cell necrosis and cytolysis lead to release of tumor markers in the blood and other body fluids

- Monoclonal antibodies (previously labeled with tracers) are used for determining the tumor markers concentration

- In accordance of tracer: immunoradiometric, enzymatic, fluorometric and luminimimetric methods
Tumor markers- indications

• Follow up during treatment; decreased level over 50% is significant to good therapeutic response while normalisation is in accordance to complete therapy response
• Relaps evaluation
• Screening
- Well differentiated thyroid cancer: Tg
- Breast: CA-15-3 (cancer antigen)
- Prostate: PSA
- Gynecologic tumors: CA125, TPA
- Small cell lung cancer, brain cancer: NSE (neuron specific enolase)
- Non small cell lung cancer: CYFRA 21-1 (cytokeratin fragment)
- Liver ca: AFP
- Testicular ca.: AFP i beta-HCG
- Gastrointestinal ca.: CEA, CA19-9, p53 oncogen
Non-specific markers (pancarcinoma antigens, shared by various neoplastic lesions)

- **CEA**: gastrointestinal ca., pancreatic, breast, lung cancer

- **TPA** (tissue polypeptide antigen), **TPA-M, TPS**: lung, breast, colorectal cancer